Jubbonti (denosumab-bbdz) is the first FDA-approved interchangeable biosimilar to Prolia, and Sandoz launched it in the United States on June 2, 2025, after settling a patent dispute with Amgen. Because Jubbonti is a physician-administered injection rather than a pharmacy pickup, Medicare pays for it very differently than a Part D pill: coverage runs through Medicare Part B, priced off a quarterly government formula, not a copay card at the pharmacy counter.
CoveredUSA's guide below breaks down exactly what Medicare pays for a standard 60 mg Jubbonti dose in 2026, what you owe under Original Medicare, Medicare Advantage, and Medigap, and how Jubbonti's price compares to brand-name Prolia. For the deductible and coinsurance mechanics behind these numbers, see copay vs coinsurance explained. Check Medicare Advantage plans in your state to compare formularies before your next injection.
Coverage Breakdown
| Coverage Type | Covers Jubbonti? | What You Pay Per Injection (2026) | Key Notes |
|---|---|---|---|
| Original Medicare Part B (no supplement) | Yes, as a medical benefit | About $324 to $339 (20% coinsurance) after the $283 deductible | Billed under HCPCS Q5136; paid at ASP plus 6% in 2026 |
| Medicare Advantage | Varies by plan | $0 to $500 copay depending on plan design | Must cover at least what Part B covers; check the 2026 formulary and prior auth rules |
| Original Medicare + Medigap (Plan G or N) | Yes, fully | $0 once the $283 Part B deductible is met | Medigap pays the 20% Part B coinsurance that Original Medicare leaves behind |
| No Medicare / self-pay | Not covered | About $1,600 to $1,925 cash price per 60 mg dose | Based on 2026 WAC-to-AWP list price; hospital outpatient facility fees can push this higher |
CMS republishes the Average Sales Price (ASP) used to set the Q5136 payment rate every calendar quarter, so the exact Medicare-allowed amount for Jubbonti shifts slightly throughout 2026. Your specific coinsurance depends on which quarter you receive the injection in and where you've already applied toward the 2026 Part B deductible.
Source: CMS Medicare Part B ASP Pricing Files 2026; Medicare.gov Osteoporosis Drugs Coverage
Direct Answer
Yes, Original Medicare Part B covers Jubbonti when your doctor administers it for an FDA-approved use like osteoporosis. After the 2026 Part B deductible of $283, you generally pay 20% coinsurance, about $324 to $339 per injection depending on the quarter. Medigap can bring that to $0. Medicare Advantage plans typically use a flat copay instead, ranging from $0 to $500 per injection.
What Original Medicare Part B Covers for Jubbonti in 2026
Jubbonti falls under Medicare Part B, not Part D, because it is a physician-administered injectable rather than a self-administered pharmacy drug. Providers bill Jubbonti under HCPCS code Q5136 (denosumab-bbdz, 1 mg per unit), and CMS reimburses at the drug's Average Sales Price (ASP) plus 6%. Because Jubbonti is FDA-approved as an interchangeable biosimilar to Prolia, Medicare covers it for the same indications: postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis at high fracture risk, bone loss from hormone-ablation therapy for certain cancers, and glucocorticoid-induced osteoporosis.
Medicare also has a narrower, separate pathway: the home health osteoporosis drug benefit, which can be billed under either Medicare Part A or Part B depending on your home health episode. If you're a woman whose injectable osteoporosis drug is connected to a bone fracture related to postmenopausal osteoporosis, your doctor certifies you cannot self-inject, and no willing or able caregiver is available, Medicare can pay 100% of both the drug and the home health nurse's visit, with no coinsurance. This is a narrow statutory exception; most Jubbonti injections happen in a doctor's office or outpatient clinic under the standard 20% Part B coinsurance rule described above.
Your Jubbonti Cost Breakdown With Medicare (2026)
CMS updates the ASP-based payment rate for Q5136 every calendar quarter in 2026: about $28.23 per mg in Q1, $27.91 per mg in Q2, $27.67 per mg in Q3, and a preliminary $26.99 per mg in Q4. A standard Jubbonti dose for osteoporosis is 60 mg given once every six months, so the Medicare-allowed amount per injection ranges from roughly $1,620 to $1,694 across the year.
Under Original Medicare with no supplemental coverage, you pay the 2026 Part B annual deductible of $283 first (if you haven't already met it with other Part B services), then 20% coinsurance on the Medicare-allowed amount, roughly $324 to $339 per injection. Since Jubbonti is typically dosed twice a year, your total annual coinsurance runs about $648 to $678, on top of the once-a-year $283 deductible.
- Medicare-allowed amount per 60 mg dose (2026): about $1,620 to $1,694
- Your 20% coinsurance per injection: about $324 to $339
- 2026 Part B annual deductible (paid once, if not already met): $283
- Estimated total annual cost with 2 injections and no supplement: about $931 to $961
What Medicare Advantage Plans Add or Change for Jubbonti
Medicare Advantage plans must cover Jubbonti at least as well as Original Medicare Part B, but they can structure your cost-sharing differently. Observed Medicare Advantage copays for Jubbonti range from $0 to $500 per injection depending on the plan and whether the drug is on a preferred or non-preferred tier of the medical benefit. UnitedHealthcare and most Humana Medicare Advantage plans switched their preferred denosumab product from brand-name Prolia to the lower-cost biosimilar Jubbonti effective September 1, 2025, which can affect your prior authorization requirements even if your dose and diagnosis haven't changed.
Before your appointment, call the member services number on your Medicare Advantage card and ask three questions: is Jubbonti on the medical benefit formulary, does it require prior authorization, and what is your exact copay or coinsurance for HCPCS code Q5136. Your plan's annual out-of-pocket maximum, which Original Medicare does not have, also caps your total 2026 spending once you hit that limit.
